Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C

Tartaglia LJ, Gupte S, Pastores KC, et al. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. J Virol. 2020;94(10):e01860-19. Published 2020 May 4. doi:10.1128/JVI.01860-19

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP Jr, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. 2019 Jun;570(7762):468-473.

Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability and stability while preserving full neutralization activity.

Kerwin BA, Bennett C, Brodsky Y, Clark R, Floyd JA, Gillespie A, Mayer BT, McClure M, Siska C, Seaman MS, Seaton KE, Shaver J, Tomaras GD, Yates NL, Ketchem RR. Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability and stability while preserving full neutralization activity. J Pharm Sci. 2019 Jul 23;. doi: 10.1016/j.xphs.2019.07.009. [Epub ahead of print].

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.

Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nat Commun. 2019 Jul 1;10(1):2898.

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.

Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity. 2019 Jun 18;50(6):1513-1529.e9.

A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection.

Silver ZA, Dickinson GM, Seaman MS, Desrosiers RC. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection. J Virol. 2019 May 15;93(10). doi: 10.1128/JVI.00094-19.

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, et al. (2019) Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLOS ONE 14(8): e0219142.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. J Virol. 2019 Feb 1;93(3).

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. J Virol. 2019 Feb 1;93(3).

HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72.